|
|
|
|
|
|
|
|
|
|
Reuters
"....The court's ruling came in a challenge launched by medical researchers and others to seven patents owned by or licensed to Salt Lake City, Utah-based biotechnology company Myriad Genetics Inc on two genes linked to breast and ovarian cancer.......
".....The compromise outcome, which had been recommended to the justices by the Obama administration, will have less impact on Myriad than if the court had barred patents for all types of human genetic material. The Myriad patents in dispute will all expire by 2015, though the company said it holds other patents that will protect its tests through 2018 and potentially beyond......
"....."Based on our initial review of the court's decision, we expect it will open opportunities for Quest Diagnostics to develop new testing services, including in the area of hereditary breast cancer," Quest spokeswoman Wendy Bost said......
".....Myriad said the decision left intact 24 different patents that relate to the BRACAnalysis test. Peter Meldrum, Myriad's president and CEO, said the ruling ensures "strong intellectual property protection for our BRACAnalysis test moving forward."......
The case is Association for Molecular Pathology v. Myriad Genetics, U.S. Supreme Court, No. 12-398.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.